Log In Sign up
The largest database of trusted experimental protocols
> Devices > Medical Device > Defibrillators

Defibrillators

Defibrillators are lifesaving medical devices used to restore normal heart rhythm in individuals experiencing sudden cardiac arrest.
These devices deliver a controlled electric shock to the heart, terminating abnormal heart rhythms and allowing the heart to reestablish an effective pumping action.
Defibrillators come in various forms, including automated external defibrillators (AEDs) for public access and implantable cardioverter-defibrillators (ICDs) for individuals at high risk of cardiac arrhythmias.
Proper use and maintenance of defibrillators is crucial for maximizing their effectiveness in emergency situations.
Reasearchers leveraging PubCompare.ai's AI-driven platform can optimize their defibrillator research protocols to enhance reproducibility and accuracy, locating the best available methods and products for their needs.

Most cited protocols related to «Defibrillators»

1
MASALA Study Eligibility Criteria
To be eligible for the MASALA study participants had to have (1) South Asian ancestry defined by having at least 3 grandparents born in one of the following countries: India, Pakistan, Bangladesh, Nepal, or Sri Lanka; and (2) age between 40 and 79 years; (3) ability to speak and/or read English, Hindi or Urdu. A pilot study called the Metabolic syndrome and Atherosclerosis in South Asians Living in America (NIH grant #K23 HL080026) had similar eligibility criteria and methods as this larger study. The 150 participants enrolled in the pilot study were eligible to enroll in the current MASALA study.
We used identical exclusion criteria to MESA12 (link) which included having a physician diagnosed heart attack, stroke or transient ischemic attack, heart failure, angina, use of nitroglycerin, or those with a history of cardiovascular procedures such as coronary artery bypass graft surgery, angioplasty, valve replacement, pacemaker or defibrillator implantation, or any surgery on the heart or arteries. Those with current atrial fibrillation or in active treatment for cancer were excluded. Those with life expectancy < 5 years due to a serious medical illness, impaired cognitive ability as judged by the reviewer, plans to move out of the study region in the next 5 years, or those living in a nursing home or on a waiting list were also excluded. Due to CT scanner limitations, those weighing over 300 lbs. were excluded.
Kanaya A.M., Kandula N., Herrington D., Budoff M.J., Hulley S., Vittinghoff E, & Liu K. (2013). Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study: Objectives, Methods, and Cohort Description. Clinical Cardiology, 36(12), 713-720.
Publication 2013
Angina Pectoris Angioplasty Arteries Asian Persons Atherosclerosis Atrial Fibrillation Cardiovascular System CAT SCANNERS X RAY Cerebrovascular Accident Childbirth Cognition Congestive Heart Failure Coronary Artery Bypass Surgery Defibrillators Eligibility Determination Grandparent Infantile Neuroaxonal Dystrophy Malignant Neoplasms Metabolic Syndrome X Myocardial Infarction Nitroglycerin Ovum Implantation Pacemaker, Artificial Cardiac Physicians South Asian People Surgical Procedure, Cardiac Transient Ischemic Attack
2
Subclinical CVD Risk in Rheumatoid Arthritis
The Evaluation of Subclinical Cardiovascular disease And Predictors of Events in Rheumatoid Arthritis Study (ESCAPE RA) is a cohort study of the prevalence, progression, and risk factors for subclinical CVD in men and women with RA. The ESCAPE RA study was designed with identical inclusion and exclusion criteria (except for the diagnosis of RA) to MESA, a population-based cohort study of subclinical CVD with similar objectives. The ESCAPE RA inclusion criteria were: fulfillment of American College of Rheumatology criteria for the classification of RA [18 (link)] of ≥ 6 months; and age 45 to 84 years. Medical records were reviewed for each participant to confirm diagnosis. Exclusion criteria were: prevalent CVD prior to enrollment (prior CVD was defined as self-reported or physician-diagnosed myocardial infarction, heart failure, coronary artery revascularization, angioplasty, peripheral vascular disease or procedures (excluding varicose vein procedures), implanted pacemaker or defibrillator devices, and current atrial fibrillation); weight exceeding 300 pounds (due to imaging equipment limitations); and CT scan of the chest within 6 months prior to enrollment (to limit radiation exposure).
Given the greater prevalence of RA in women, we set a recruitment goal of at least 40% males to enable gender-specific analyses, and recruited 195 patients from the Johns Hopkins Arthritis Center and by referral from community rheumatologists.
The study was approved by the Johns Hopkins Hospital Institutional Review Board and MESA, with all participants providing informed consent prior to enrollment. Enrollment occurred from October 2004 through May 2006.
Giles J.T., Szklo M., Post W., Petri M., Blumenthal R.S., Lam G., Gelber A.C., Detrano R., Scott WW J.r., Kronmal R.A, & Bathon J.M. (2009). Coronary arterial calcification in rheumatoid arthritis: comparison with the Multi-Ethnic Study of Atherosclerosis. Arthritis Research & Therapy, 11(2), R36.
Full text: Click here
Publication 2009
Angioplasty Artery, Coronary Arthritis Atrial Fibrillation Cardiovascular Diseases Chest Congestive Heart Failure Defibrillators Disease Progression Ethics Committees, Research Gender Males Medical Devices Myocardial Infarction Pacemaker, Artificial Cardiac Patients Peripheral Vascular Diseases Physicians Radiation Exposure Rheumatoid Arthritis Rheumatologist Satisfaction Varices Woman X-Ray Computed Tomography
3
Comprehensive Cardiovascular Evaluation in Incident Dialysis Patients
We screened a total of 1736 individuals identified as incident dialysis patients by dialysis staff of which, 943 (54.3%) met eligibility criteria. Those with either a pacemaker (n = 89) or an automatic implanatable cardioverter defibrillator (n = 70) at time of screening were ineligible to participate in the study in addition to other reasons such as nursing home residents, inability to consent, history of recent cancer and history of peritoneal dialysis or transplantation. A total of 574 participants (61% of 943) were consented into the study with 402 completing the baseline cardiac evaluation. The median follow-up time was 1.78 years (range 0–5.43) with 52 participants who underwent kidney transplantation, 25 who transferred to peritoneal dialysis, and 106 who died as of July 31, 2014.
The PACE study population is predominantly younger and comprised of a larger proportion of African Americans than described in the national Comprehensive Dialysis Study (CDS) or the USRDS (Table 4) [1 ,85 (link)]. In Table 5, the baseline demographic and clinical characteristics are shown for the study population enrolled. The baseline characteristics of the cardiac measures, laboratory tests and medications are also provided for those who have completed the initial study visit with the detailed cardiac evaluation.

PACE study population and comparison to incident US dialysis cohorts

Dialysis study
PACE
CDS*
USRDS*
Time period
2009-2012
2005-2007
2008
Incident population, n5741646110,175
African American66%28%28.8%
Mean age, yrs566062.8
Younger age <65 years73%61.8%52.8%
Diabetes53%52.6%44.9%
Mean BMI, kg/m229.329.828.4
Male54%55.1%57.6%
Nutritional assessment, n402361None
Follow-upAnnual in-person clinical evaluations semi-annual phone interviewsPassivePassive
Cardiac evaluationSignal averaged ECGNoneNone
Echocardiogram
Cardiac CT calcium and angiography
Pulse wave velocity
Ankle brachial index
Hospitalizations/MortalityAdjudicatedPassivePassive
Baseline specimen collection402269None
Follow-up specimen collectionYesNoneNone

*CDS-Comprehensive Dialysis Study 1646 completed phone interview; USRDS- United States Renal Data Systems.

Baseline demographic and clinical characteristics of all enrolled PACE participants (n = 574) and completed cardiovascular study visit (n = 402)

Characteristics
All PACE participants
Completed cardiovascular visit*
Demographic
Male, n (%)319 (56)233 (59)
African-American, n (%)397 (69)288 (72)
Age in years, mean ± SD56 (13.5)55 (13.2)
Education, % graduated high school62248 (63)
Employment, % employed1247 (12)
Marital status, % married3129
Dialysis characteristics
Three times a week dialysis, n (%)566 (98.6)397 (98.8)
Three to four hour dialysis session, n (%)505 (88.0)353 (87.8)
Polyflux membrane, n (%)446 (77.7)306 (86.4)
Arteriovenous fistula access, n (%)163 (28.7)122 (30.3)
Self reported
Smoking, % ever smoker5960
Body mass index kg/m2, mean ± SD29.4 (7.9)29.3 (7.8)
CVD, % diagnosed4445
CHF, % diagnosed2325
Diabetes, % diagnosed5455
Cardiovascular study visit
Systolic blood pressure mmHg, mean ± SDn/a137 (25)
Diastolic blood pressure mmHg, mean ± SDn/a75 (15)
Waist to hip ration/a0.95 (0.08)
Frailty, % diagnosedn/a40
Average literacy, meann/aGrade 8
Cognitively impaired, % diagnosedn/a14
Depression, % diagnosedn/a17
Medications use
Betablocker, %n/a58
ACEI/ARB, %n/a44
Calcium channel blocker, %n/a60
Statins, %n/a52
Intradialytic labs
Ionized calcium mean ± SD. mmol/Ln/a1.15 (0.07)
Magnesium mean ± SD, mg/dLn/a1.76 (0.24)

*Cardiovascular study visits were conducted at the Institute for Clinical and Translational Research and the Cardiology Research Laboratory.

Parekh R.S., Meoni L.A., Jaar B.G., Sozio S.M., Shafi T., Tomaselli G.F., Lima J.A., Tereshchenko L.G., Estrella M.M, & Kao W.H. (2015). Rationale and design for the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study. BMC Nephrology, 16, 63.
Full text: Click here
Publication 2015
African American Arm, Upper Blood Pressure Calcium, Dietary Cardiovascular System Defibrillators Dialysis Eligibility Determination Fistula, Arteriovenous Heart Implantable Defibrillator Kidney Kidney Transplantation Magnesium Malignant Neoplasms Nutrition Assessment Pacemaker, Artificial Cardiac Patients Peritoneal Dialysis Pharmaceutical Preparations Pressure, Diastolic Tissue, Membrane Transplantation Youth
4
ECG Downsampling and HRV Analysis
The study utilized ECG signals collected for previously reported research on the utility of HRV in the diagnosis of acute cholinesterase inhibitor poisoning, which involved 83 adult patients who visited an emergency department with the chief complaint of acute poisoning in the earliest period of the patients' stay in the emergency department that provided data of appropriate quality. Emergency treatments, including tracheal intubation, intravenous access, and the first dose of an antidote such as atropine, were given prior to signal acquisition [6 ]. The ECG signals were acquired and digitized at a 1,000-Hz frequency using a custom-built sampling device from the analog ECG output port of a LIFEPAK 20 monitor-defibrillator (Physio-Control, Redmond, WA, USA). The Physio-Toolkit software package was used to process the ECG signals [11 (link)]. The original 1,000-Hz ECG signals were down-sampled to 500-, 250-, 100-, and 50-Hz sampling frequencies with the xform command, which applies linear interpolation when altering sampling frequencies. The timing of QRS waves was detected by the gqrs command and subsequently converted into R–R interval data with the ann2rr command. One case was excluded from further analysis because the gqrs function could not reliably detect QRS complexes from the data on 1,000-Hz signals.
The R–R interval data were analyzed for time-domain, frequency-domain, and nonlinear HRV parameters using Kubios HRV Standard version 3.0 (Kubios Oy Ltd., Kuopio, Finland) from 5-minute sections of the signal tracing [12 (link)]. The HRV parameters used for further analysis and their definitions are summarized in Table 1. Parameters derived from data on the 500-, 250-, 100-, and 50-Hz down-sampled frequencies were compared to those derived from data on 1,000-Hz signals, and Lin's concordance correlation coefficients (CCC) with respective 95% confidence intervals (CI) were calculated. The sampling frequencies were considered unacceptable when the CCCs for the respective parameters were <0.9 [13 (link)14 ]. Bland-Altman analysis was performed to determine the limits of agreement between results from different frequencies. MedCalc Software version 18.2.1 (Med-Calc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018) was used for statistical analysis.
Kwon O., Jeong J., Kim H.B., Kwon I.H., Park S.Y., Kim J.E, & Choi Y. (2018). Electrocardiogram Sampling Frequency Range Acceptable for Heart Rate Variability Analysis. Healthcare Informatics Research, 24(3), 198-206.
Publication 2018
Adult Antidote Atropine Cholinesterase Inhibitors Defibrillators Diagnosis Intubation, Intratracheal Medical Devices Patients Treatment, Emergency
5
Non-Invasive Liver Assessment for NAFLD
Eligible patients were aged 18 years or older, able to give written informed consent, and scheduled (independently from this study) to have a liver biopsy for investigation of suspected NAFLD (usually as a result of abnormal liver enzymes and an ultrasound scan showing an echobright liver) within 2 weeks before or after LSM by VCTE and CAP measurements. All patients gave written informed consent to participate in the study. Eligible patients were negative for hepatitis B surface antigen, anti-hepatitis C virus antibody, hepatitis C virus RNA, and hepatitis B virus DNA. Patients were excluded in case of ascites, pregnancy, active implantable medical device (such as pacemaker or defibrillator), liver transplantation, cardiac failure or clinically significant valvular disease, haemochromatosis, refusal to have liver biopsy or blood tests, alcohol consumption above recommended limits (>14 units per week for women and >21 units per week for men), diagnosis of active malignancy or other terminal disease, or participation in another clinical trial within the previous 30 days. Age, sex, body-mass index (BMI), and presence of diabetes, hypertension, and hypercholesterolaemia were recorded for each patient. A 12 h fasting blood sample was obtained locally and then shipped to a central laboratory for assessment.
Newsome P.N., Sasso M., Deeks J.J., Paredes A., Boursier J., Chan W.K., Yilmaz Y., Czernichow S., Zheng M.H., Wong V.W., Allison M., Tsochatzis E., Anstee Q.M., Sheridan D.A., Eddowes P.J., Guha I.N., Cobbold J.F., Paradis V., Bedossa P., Miette V., Fournier-Poizat C., Sandrin L, & Harrison S.A. (2020). FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet. Gastroenterology & Hepatology, 5(4), 362-373.
Full text: Click here
Publication 2020
Ascites Biopsy BLOOD B virus, Hepatitis Defibrillators Diabetes Mellitus Diagnosis Enzymes Heart Failure Hematologic Tests Hemochromatosis Hepatitis B Surface Antigens Hepatitis C Antibodies Hepatitis C virus High Blood Pressures Hypercholesterolemia Index, Body Mass Liver Liver Transplantations Malignant Neoplasms Medical Devices Non-alcoholic Fatty Liver Disease Pacemaker, Artificial Cardiac Patients Pregnancy Ultrasonography Woman

Most recents protocols related to «Defibrillators»

1
Adult ICU Expansion in Amhara Region
The study was conducted in comprehensive specialized hospitals in the Amhara region, Northwest Ethiopia. There are five comprehensive specialized hospitals in Northwest Ethiopia; namely the University of Gondar, Tibebe Ghion, Felege Hiwot, Debre Markos, and Debre Tabor comprehensive specialized hospitals. Felege Hiwot and Tibebe Ghion comprehensive specialized hospitals are found in Bahir Dar (the capital city of Amhara regional state) 565 km far from Addis Ababa. Debre Markos and Gondar comprehensive specialized hospitals are found 299 and 730 km far from Addis Ababa, respectively [31 (link)]. The first adult ICU in the Amhara region was started in 2009 G.C at Felege Hiwot comprehensive specialized hospital with three beds and two mechanical ventilators. Subsequently, it was expanded to the University of Gondar comprehensive specialized teaching hospital, Debre Markos and Tibebe Ghion comprehensive specialized hospitals in 2011, 2016, and 2019 G.C, respectively. Currently, these hospitals have a total of 44 functional adult ICU beds which has been rendering services for critical patients. The average number of admission to the ICU was 12 patients per month for each hospital, and about 40% of these were trauma patients. The ICUs are providing a similar level of care equipped with mechanical ventilators, noninvasive hemodynamic monitoring devices, portable ultrasounds, defibrillators, and infusion pumps.
Messelu M.A., Tilahun A.D., Beko Z.W., Endris H., Belayneh A.G, & Tesema G.A. (2023). Incidence and predictors of mortality among adult trauma patients admitted to the intensive care units of comprehensive specialized hospitals in Northwest Ethiopia. European Journal of Medical Research, 28, 113.
Full text: Click here
Publication 2023
Adult Defibrillators Infusion Pump Mechanical Ventilator Medical Devices Patients Ultrasonography Wounds and Injuries
2
Postoperative ICU Monitoring After Abdominal Surgery
From July 2020 to February 2022, we performed a prospective observational study in a 22-bed ICU of a single tertiary hospital. All patients aged over 18 years who were admitted to the ICU after abdominal surgery performed under general anesthesia were eligible for inclusion, regardless of the surgical technique, such as laparotomy, laparoscopic or robotic surgery. If the patient underwent endovascular surgery or percutaneous transluminal angioplasty, they were excluded from enrollment. However, cases of open thrombectomy or emergent exploration due to abdominal aortic aneurysmal rupture were enrolled. Patients who met any one of these criteria were excluded from study enrollment: (1) those who had any contraindication or significant confounders of BIA, such as any prosthetic medical devices including an implanted cardiac defibrillator, pacemaker, or metallic intravascular device, or any bone fixation implants or limb amputation; (2) pregnant women; (3) those who underwent extracorporeal membrane oxygenation treatment before surgery; (4) those who were readmitted within 48 h after discharge from the ICU or died within 72 h after surgery; (5) those who were admitted to the ICU only for medical causes without surgery, and (6) those lacking or missing essential BIA data. Patients such as those receiving hemodialysis for end-stage renal disease or severe acute kidney injury that could be significant confounders of laboratory inflammation tests such as presepsin (18 (link), 19 (link)), were also excluded from the study analysis. Written informed consent was obtained from each patient and the recruiting data, including demographics, disease profile, and laboratory results, were reviewed retrospectively. This study was approved and carefully monitored by our Institutional Review Board (No. IRB; KC22RISI0346), and was performed in accordance with the 1964 Declaration of Helsinki and its later amendments.
Lee G.R, & Kim E.Y. (2023). Usefulness of phase angle on bioelectrical impedance analysis as a surveillance tool for postoperative infection in critically ill patients. Frontiers in Medicine, 10, 1111727.
Full text: Click here
Publication 2023
Abdomen Amputation Aortic Aneurysm, Abdominal Aortic Aneurysm, Ruptured Bones Defibrillators Extracorporeal Membrane Oxygenation General Anesthesia Heart Hemodialysis Inflammation Kidney Failure, Acute Kidney Failure, Chronic Laparoscopy Laparotomy Medical Devices Metals Operative Surgical Procedures Pacemaker, Artificial Cardiac Patient Discharge Patients Percutaneous Transluminal Angioplasty Pregnant Women Prosthesis Robotic Surgical Procedures Thrombectomy
3
Comparing Hemodynamic Markers in Heart Failure
Our research protocol was developed and approved by the institutional review board (IRB). The study was conducted in compliance with the ethical standards of the responsible institution on human subjects as well as with the Helsinki Declaration. We included patients with history of New York Heart Association (NYHA) class III systolic HF longer than 6 months with a pre-implanted intracardiac defibrillator (ICD) capable of monitoring TI (St. Jude Medical’s Corvue™ Birmingham, MN) and pre-implanted CardioMEMs™ remote HF monitoring device. Eligible patients were identified using the Merlin.net™ database of patients with CardioMEMs™ device previously implanted at our institution (Ascension Providence Hospital, Southfield) and cross-checking them with our pacemaker clinic to assess whether they have implanted ICDs which can measure TI (St. Jude Medical’s Corvue™). After initial identification, subjects were brought in for a routine clinic visit where consent for enrolment in the study was obtained. During this initial visit, each patient was assessed for volume status and current medications, baseline assessment of pulmonary artery diastolic pressure (PAdP) via CardioMems device along with their St. Jude ICD interrogation. Patients were subsequently prospectively followed over a period of 12 weeks. Medication changes, if needed, were left to the treating cardiologist’s discretion.
Remote hemodynamic data were acquired from the St. Jude portal (Merlin) for weekly CardioMems PAdP transmissions and biweekly transmissions from CorVue TI recordings. Weekly PAdP values (mm Hg) were averaged (defined to be valid for at least three valid transmissions per week) for an individual subject during the follow-up duration.
TI data were acquired from St. Jude’s CorVue remote device monitoring system. The weekly values (ohms) were acquired from reconstructed graphs/curves using the web-based software program, WebPlotDigitizer [20 ]. For comparison across a uniform variable for the two methods, weekly PAdP measurements were averaged. Weekly percentage change was then calculated as: Weekly percentage change = (week 2 - week1)/week 1 × 100.
Aggarwal A., Khan Z., Machado C, & Zughaib M. (2023). Assessing Correlation Between Thoracic Impedance and Remotely Monitored Pulmonary Artery Pressure in Chronic Systolic Heart Failure. Cardiology Research, 14(1), 32-37.
Publication 2023
Cardiologists Clinic Visits Defibrillators Ethics Committees, Research Heart Hemodynamics Implantable Defibrillator Medical Devices nf2 Gene Pacemaker, Artificial Cardiac Patients Pharmaceutical Preparations phenylacetic dipalmitate Pressure, Diastolic Pulmonary Artery Systole Transmission, Communicable Disease
4
Cardiac Resynchronization Therapy Utilization in CKD
Data were obtained from the Nationwide Inpatient Sample (NIS) database published by the Healthcare Cost and Utilization Project (HCUP). The NIS database is the largest publicly available all-payer inpatient health care database in the United States and contains data from >7 million hospital stays each year.5 ,6 Stratified random sampling ensures that the NIS is representative of the U.S. population. National estimates can be obtained using the discharge weights assigned to the hospitalization records.7 Institutional review board approval was not needed for this study, as all patient information is de-identified within the NIS. A detailed overview of HCUP NIS is available at https://www.hcup-us.ahrq.gov/nisoverview.jsp.
We excluded hospitalizations of patients <18 years of age. We used International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to identify patients with a primary procedure code for CRT-P (biventricular pacemaker only, code 00.50) or CRT-D (biventricular pacemaker with a defibrillator, code 00.51) implantation. These codes have been used in previous NIS-based studies.8 (link),9 (link) We excluded patients with renal transplant (ICD-9-CM codes V42.0 and 996.81) from the cohort of hospitalizations for CRT implantation. We then identified patients hospitalized with a concurrent CKD diagnosis using ICD-9-CM diagnosis codes 585.1–585.5 (CKD 1–5, respectively) and 585.9 (CKD, unspecified). Figure S1 shows a graphical representation of the sequentially derived study cohort. This method has been used in other NIS-based studies to correctly identify patients hospitalized with CKD.10 (link),11 (link)All hospitalizations were stratified according to age, sex, race, elective versus non-elective admission, disposition status, comorbidities, and complications. The description of these variables can be found in Table S1. All analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). Relevant hospital- and discharge-level weights were applied to the dataset to estimate the total number of hospitalizations involving CRT-P and CRT-D device implantations during hospitalizations involving a concurrent diagnosis of CKD in the United States from 2008–2014. Outcomes were compared using the chi-squared test for categorical variables and Student’s t test or linear regression analysis for continuous variables.
Kichloo A., Solanki D., Berger R., Jamal S., Albosta M., Aljadah M., Khan M.Z, & Kanjwal K. (2023). Trends in the Use and Complications of Cardiac Resynchronization Therapy Device Implantation in Chronic Kidney Disease Patients. The Journal of Innovations in Cardiac Rhythm Management, 14(2), 5339-5347.
Full text: Click here
Publication 2023
Defibrillators Diagnosis Ethics Committees, Research Hospitalization Inpatient Kidney Transplantation Medical Devices Ovum Implantation Pacemaker, Artificial Cardiac Patient Discharge Patients Student
5
Remote Monitoring for Cardiac Devices
This was a single-center, prospective, non-randomized format study. Rolling enrollment was used until the achievement of 2 RC sessions per patient, resulting in a total of 150 patients.
We enrolled patients with pacemakers and defibrillators able to be monitored using the Medtronic CareLink™ network as an inclusion criterion. The protocol involved 2 clinical follow-up sessions using the at-home video-conferencing and RC session modality. All patients signed an informed consent form before enrollment. The protocol and informed consent were evaluated, approved, and supervised by the designated institutional review board regulatory agency.
The timing between sessions was not pre-specified, but we aimed for it to be <12 months. The study RC sessions did not preclude patients to be seen in the office or hospital as deemed necessary in between the remote sessions. The patients included were a mix of new patients enrolled for postoperative follow-up and established patients with devices interested in trying a new modality of service.
Kloosterman E.M., Rosman J.Z., Berkowitz E.J., Rosenbaum M, & Wettenstein Z. (2023). Remote-control Interrogation, Testing, and Reprogramming of Cardiac Implantable Electronic Devices with Telehealth Protocol for the Management of Patients at Home: The DOMUM REMOTUS Study. The Journal of Innovations in Cardiac Rhythm Management, 14(2), 5348-5354.
Full text: Click here
Publication 2023
Defibrillators Ethics Committees, Research Medical Devices Pacemaker, Artificial Cardiac Patients Vision

Top products related to «Defibrillators»

1
Simman 3g by Laerdal
Sourced in Norway
SimMan 3G is a high-fidelity patient simulator designed for healthcare training and education. It is capable of simulating a wide range of medical conditions and patient scenarios to help healthcare professionals develop and practice their skills.
2
Man wireless by Ambu
Sourced in Germany
Ambu Man Wireless is a wireless manikin designed for healthcare training and simulation. It provides realistic airway and breathing functionality for practicing essential skills such as ventilation, CPR, and airway management. The manikin is battery-powered and does not require any cables or wires, allowing for flexibility in training scenarios.
3
Heartstart mrx by Philips
The HeartStart MRx is a portable defibrillator and monitor designed for use in emergency medical situations. It provides basic life support capabilities, including defibrillation, monitoring, and pacing functions. The device is intended for use by trained medical professionals to assist in the treatment of cardiac emergencies.
4
Bc 418 by Tanita
Sourced in Japan, United States, Germany, United Kingdom
The BC-418 is a body composition analyzer that measures body weight, body fat percentage, and other body composition metrics through bioelectrical impedance analysis. It provides accurate and reliable data for health and fitness assessments.
5
Simbaby by Laerdal
Sourced in Norway
SimBaby is a pediatric patient simulator designed for healthcare training. It features realistic anatomy and physiological functions to provide a lifelike simulation experience. The core function of SimBaby is to enable healthcare professionals to practice and develop their skills in pediatric care and emergency response.
6
Cognis by Boston Scientific
Sourced in United States, New Zealand
Cognis is a laboratory equipment product designed to perform advanced signal processing and waveform analysis. It is a versatile tool that captures, processes, and analyzes complex signals across various applications.
7
Heartstart mrx defibrillator with q cpr option by Philips
Sourced in Norway
The Philips Heartstart MRx defibrillator with Q-CPR option is a device designed to provide defibrillation and CPR assistance. It features automated cardiac monitoring capabilities and supports manual and semi-automatic defibrillation modes.
8
Heartstart mrx monitor defibrillators by Philips
Sourced in United States
The Philips Heartstart MRx monitor-defibrillators are medical devices designed for emergency care and critical response situations. The core function of the Heartstart MRx is to monitor a patient's vital signs and provide defibrillation therapy when necessary.
9
Heart start event review by Philips
Sourced in United States
The Philips HeartStart Event Review is a compact and portable device designed to review and manage data from automated external defibrillators (AEDs). It allows users to download, review, and analyze event data from Philips AEDs, providing a comprehensive overview of cardiac events and device performance.
10
Crt d by Biotronik
Sourced in Germany
The CRT-D is a cardiac resynchronization therapy defibrillator device designed to help manage heart failure. It provides cardiac resynchronization therapy and defibrillation capabilities to patients as needed.

More about "Defibrillators"

Defibrillators are critical medical devices used to resuscitate individuals experiencing sudden cardiac arrest.
These lifesaving machines deliver a controlled electric shock to the heart, terminating abnormal rhythms and allowing the heart to resume effective pumping.
Defibrillators come in various forms, including automated external defibrillators (AEDs) for public access and implantable cardioverter-defibrillators (ICDs) for high-risk patients.
Proper use and maintenance of these devices is crucial for maximizing their effectiveness in emergency situations.
Researchers can leverage innovative AI-driven platforms like PubCompare.ai to optimize their defibrillator research protocols, enhancing reproducibility and accuracy.
By locating the best available methods and products from literature, pre-prints, and patents, researchers can ensure they are using the most effective approaches for their needs.
Tools like the SimMan 3G, Ambu Man Wireless, HeartStart MRx, BC-418, and SimBaby simulators can also be utilized to test and validate defibrillator performance.
Additionally, features like the Cognis CRT-D and Heartstart MRx monitor-defibrillator with Q-CPR option provide advanced functionalities to support cardiac care.
The Philips Heart Start Event Review software can also be leveraged to analyze defibrillator usage and outcomes.
By embracing these innovative technologies and research optimization strategies, defibrillator research can be taken to new heights, ultimately improving patient outcomes in emergency situations.